antibacterial potential of lucilia sericata excretions/secretions in bovine cutaneous wounds

In the last decade, many patients worldwide have treated their injuries with maggots, so many doctors recognize maggot therapy as an influential supplement in traditional medicine.  this study examined the excretions/secretions (es) of lucilia sericata larvae on fibroblast cells and isolated bacteria from bovine chronic wounds. the viability of bovine fibroblast cells was assessed using mtt assay. the results showed that the minimum inhibitory concentration (mic) of larval es on staphylococcus aureus, pseudomonas aeruginosa, and escherichia coli was 40 mg ml-1. the disk diffusion mic experiment revealed that larval es can control the growth of bacteria from bovine chronic wounds. the mtt assay showed that 0.1, 0.05, and 0.025 mg ml-1 larval es did not affect the survival of bovine fibroblasts. in comparison, concentrations equal to or greater than 0.25 mg ml-1 caused a significant decline in the proliferation and viability of the fibroblast cells (p<0.05). in conclusion, the maggot l. sericata es showed control bovine chronic wound bacteria in vitro less than 0.25 mg ml-1, but using more can produce side effects on living cells. in vivo studies are recommended for the evaluation of the maggot l. sericata es on cutaneous bovine wounds.